AVBCC 2020 Summit

The COVID-19 pandemic has allowed telemedicine to be widely adopted for the delivery of cancer care. In this session, experts discuss some of the benefits of this technology, as well as key legal issues that need to be addressed.

Value-based contracts (VBCs) are the future of healthcare. However, many barriers to entry exist for the exploration of these contracts. In this discussion, experts offer legal perspectives on the goals of VBCs and potential hurdles and solutions.

As the COVID-19 pandemic continues, patients with cancer face numerous challenges. Healthcare professionals continue to play a critical role in advocating for their patients’ access to care.

In recent years, there has been an increase in the number of innovative treatments developed for the management of patients with cancer, including CAR T-cell therapies. In this session, experts from all facets of healthcare offered their perspectives on the use of these agents in the context of value-based care.

Virtual care, which has existed in the background of medicine for years, has now come to the forefront during the COVID-19 pandemic. Experts on telehealth weighed in on the impact of this technology on cancer care and what is on the horizon.

In this session, a panel of experts from all branches of healthcare make predictions on the cancer care forecast post-election.

The current climate of COVID-19 and political uncertainty has made an impact on the future of cancer care. Top CEOs give their perspective on what lies ahead.

In this session, expert panelists discuss the impact of COVID-19, future trends in access and management, and upcoming trends in oncology.

HUB programs ensure that cancer care is delivered efficiently. However, many patients and healthcare providers need more education on the services offered for these programs to be effective. In this session, experts discuss common challenges of HUB programs and the future of these support services.

The COVID-19 pandemic exposed many cracks in today’s healthcare system, including underrepresentation of minorities in clinical trials. In this session, experts discuss this important issue, as well as strategies for effectively breaking down current health equity barriers.